Advertisement

Document › Details
VectivBio Holding AG. (4/8/21). "Press Release: VectivBio Announces Pricing of Initial Public Offering". Basel.
![]() |
Region | United States (USA) |
![]() |
Organisation | VectivBio Holding AG (Nasdaq: VECT) |
Group | VectivBio (Group) | |
Organisation 2 | Nasdaq Global Market | |
Group | Nasdaq OMX (Group) | |
![]() |
Product | DRUGS, ORPHAN |
Product 2 | investment banking | |
![]() |
Index term | VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market |
![]() |
Person | Morrell, Graham (Paddock Circle Advisors 201808) |
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting discounts and commissions.
Vectiv’s shares are expected to begin trading on the Nasdaq Global Select Market on Friday, April 9, 2021 under the ticker symbol “VECT.” The offering is expected to close on April 13, 2021, subject to customary closing conditions.
BofA Securities, SVB Leerink and Credit Suisse are acting as joint book-running managers for the offering. LifeSci Capital is also acting as an underwriter for the offering.
A registration statement relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 8, 2021. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at dg.prospectus_requests@bofa.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@svbleerink.com; or Credit Suisse Securities (USA) LLC Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Investors
Graham Morrell
graham.morrell@vectivbio.com
Media
Morgan Warners
+1 202 295 0124
morgan.warners@fgh.com
Record changed: 2022-05-07 |
Advertisement
![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
More documents for VectivBio (Group)
- [1] VectivBio Holding AG. (3/30/22). "Press Release: VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts". Basel....
- [2] VectivBio Holding AG. (9/21/21). "Press Release: VectivBio Announces Closing of Comet Therapeutics Acquisition". Basel....
- [3] VectivBio Holding AG. (9/8/21). "Press Release: VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary". Basel....
- [4] VectivBio Holding AG. (8/31/21). "Press Release: VectivBio to Acquire Comet Therapeutics and Host R&D Day". Basel....
- [5] VectivBio Holding AG. (4/13/21). "Press Release: VectivBio Announces Closing of $146.6 Million Initial Public Offering". Basel....
- [6] VectivBio AG. (10/15/20). "Press Release: VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases". Basel....
- [7] VectivBio AG. (1/7/20). "Press Release: VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare Diseases". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top